Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23360634 | 0.77 | NPC1 (0.46) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11375551 | 0.75 | RAB9A (0.51) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5324725 | 0.71 | ALDH1A1 (0.50) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9007952 | 0.71 | HSD17B10 (0.50) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL18741279 | 0.70 | RAB9A (0.46) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL18321230 | 0.70 | MAPT (0.70) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9465324 | 0.69 | RAB9A (0.53) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL10489897 | 0.68 | RAB9A (0.65) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5884131 | 0.68 | MEN1 (0.52) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL827403 | 0.67 | RAB9A (0.67) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102643274-B | Water-soluble tetrazolium salts | BAYER HEALTHCARE LLC | 2015-02-18 | — | — | CN | disclosed |
| EP-1851215-B1 | WATER-SOLUBLE TETRAZOLIUM SALTS | BAYER HEALTHCARE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| CN-102643274-A | Water-soluble tetrazolium salts | BAYER HEALTHCARE LLC | 2012-08-22 | — | — | CN | disclosed |
| US-7897331-B2 | Process of using a tetrazolium salt | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100255506-A1 | PROCESS OF USING A TETRAZOLIUM SALT | BAYER HEALTHCARE LLC (US) | 2010-10-07 | — | — | US | disclosed |
| US-7767822-B2 | Water-soluble tetrazolium salts | BAYER HEALTHCARE LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080125471-A1 | Water-Soluble Tetrazolium Salts | ASCENSIA DIABETES CARE HOLDINGS AG (CH) | 2008-05-29 | — | — | US | disclosed |
| CN-101115750-A | Water soluble tetrazolium salts | BAYER HEALTHCARE LLC (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1851215-A1 | WATER-SOLUBLE TETRAZOLIUM SALTS | Bayer Healthcare, LLC (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006076619-A1 | WATER-SOLUBLE TETRAZOLIUM SALTS | BAYER HEALTHCARE LLC (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-0476457-B1 | 2-Benzothiazolyl tetrazolium salt indicators | BAYER AG (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0476457-A2 | 2-Benzothiazolyl tetrazolium salt indicators | Bayer Corporation (US) | 1992-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125471-A1 | Water-Soluble Tetrazolium Salts | TST, AASDHPPT, APRT | HSD17B10 1379/4885NPC1 3854/4885RAB9A 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.